NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis $0.95 +0.18 (+23.32%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Plus Therapeutics Stock (NASDAQ:PSTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$0.81▼$1.1850-Day Range$0.57▼$2.9852-Week Range$2.90▼$23.42Volume8.13 million shsAverage Volume116,506 shsMarket Capitalization$6.54 millionP/E RatioN/ADividend YieldN/APrice Target$51.75Consensus RatingHold Company Overview Plus Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue. The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid. Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScorePSTV MarketRank™: 1.326435866825 of 5 starsPlus Therapeutics scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingPlus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialPlus Therapeutics has a consensus price target of $51.75, representing about 5,346.2% upside from its current price of $0.95.Amount of Analyst CoveragePlus Therapeutics has received no research coverage in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPlus Therapeutics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PSTV. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Plus Therapeutics is held by insiders.Percentage Held by Institutions3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PSTV Stock News HeadlinesPlus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?November 10, 2026 | americanbankingnews.comCerenome Announces Up to $20 Million Financing Facility with Royalty-Based RepaymentSeptember 10, 2026 | globenewswire.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 16 at 1:00 AM | Behind the Markets (Ad)Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20, 2026 | globenewswire.comCerenome Reports Second Quarter 2026 Financial Results and Business UpdateAugust 14, 2026 | globenewswire.comCerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered LivesAugust 13, 2026 | globenewswire.comPlus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | finanznachrichten.deCerenome Launches as an Integrated CNS Oncology CompanyJuly 31, 2026 | globenewswire.comSee More Headlines PSTV Stock Analysis - Frequently Asked Questions How have PSTV shares performed this year? Plus Therapeutics' stock was trading at $12.8075 at the beginning of the year. Since then, PSTV stock has decreased by 92.6% and is now trading at $0.9502. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its quarterly earnings results on Thursday, August, 13th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.88) by $0.43. The business earned $411 thousand during the quarter, compared to analyst estimates of $1.11 million. Plus Therapeutics had a negative net margin of 230.24% and a negative trailing twelve-month return on equity of 198.48%. When did Plus Therapeutics' stock split? Plus Therapeutics shares reverse split before market open on Thursday, April 2nd 2026.The 1-25 reverse split was announced on Tuesday, March 31st 2026. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), Plug Power (PLUG), NVIDIA (NVDA), Novavax (NVAX), OPKO Health (OPK) and Athersys (ATHX). Company Calendar Last Earnings8/13/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PSTV Previous SymbolNASDAQ:CYTX CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Price Target for Plus Therapeutics$51.75 High Price Target$75.00 Low Price Target$25.00 Potential Upside/Downside+5,346.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.39 million Net Margins-230.24% Pretax Margin-230.24% Return on Equity-198.48% Return on Assets-73.13% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book1.32Miscellaneous Outstanding Shares6,884,000Free Float6,712,000Market Cap$6.54 million OptionableNot Optionable Beta1.40 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:PSTV) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.